Malaysia · Delayed Price · Currency is MYR Duopharma Biotech Berhad Statistics
Total Valuation
KLSE:DPHARMA has a market cap or net worth of MYR 1.16 billion. The enterprise value is 1.38 billion.
| Market Cap | 1.16B |
| Enterprise Value | 1.38B |
Important Dates
The next estimated earnings date is Friday, August 14, 2026.
| Earnings Date | Aug 14, 2026 |
| Ex-Dividend Date | Mar 12, 2026 |
Share Statistics
KLSE:DPHARMA has 961.94 million shares outstanding. The number of shares has increased by 0.06% in one year.
| Current Share Class | 961.94M |
| Shares Outstanding | 961.94M |
| Shares Change (YoY) | +0.06% |
| Shares Change (QoQ) | n/a |
| Owned by Insiders (%) | 0.30% |
| Owned by Institutions (%) | 66.66% |
| Float | 529.68M |
Valuation Ratios
The trailing PE ratio is 12.59 and the forward PE ratio is 11.35. KLSE:DPHARMA's PEG ratio is 0.85.
| PE Ratio | 12.59 |
| Forward PE | 11.35 |
| PS Ratio | 1.27 |
| PB Ratio | 1.54 |
| P/TBV Ratio | 1.61 |
| P/FCF Ratio | 15.76 |
| P/OCF Ratio | 11.75 |
| PEG Ratio | 0.85 |
Enterprise Valuation
The stock's EV/EBITDA ratio is 7.65, with an EV/FCF ratio of 18.65.
| EV / Earnings | 14.89 |
| EV / Sales | 1.50 |
| EV / EBITDA | 7.65 |
| EV / EBIT | 9.87 |
| EV / FCF | 18.65 |
Financial Position
The company has a current ratio of 2.62, with a Debt / Equity ratio of 0.64.
| Current Ratio | 2.62 |
| Quick Ratio | 1.68 |
| Debt / Equity | 0.64 |
| Debt / EBITDA | 2.69 |
| Debt / FCF | 6.56 |
| Interest Coverage | 5.94 |
Financial Efficiency
Return on equity (ROE) is 12.60% and return on invested capital (ROIC) is 10.99%.
| Return on Equity (ROE) | 12.60% |
| Return on Assets (ROA) | 6.13% |
| Return on Invested Capital (ROIC) | 10.99% |
| Return on Capital Employed (ROCE) | 12.33% |
| Weighted Average Cost of Capital (WACC) | 5.49% |
| Revenue Per Employee | 468,490 |
| Profits Per Employee | 47,285 |
| Employee Count | 1,957 |
| Asset Turnover | 0.64 |
| Inventory Turnover | 2.03 |
Taxes
In the past 12 months, KLSE:DPHARMA has paid 29.04 million in taxes.
| Income Tax | 29.04M |
| Effective Tax Rate | 23.89% |
Stock Price Statistics
The stock price has decreased by -12.32% in the last 52 weeks. The beta is 0.36, so KLSE:DPHARMA's price volatility has been lower than the market average.
| Beta (5Y) | 0.36 |
| 52-Week Price Change | -12.32% |
| 50-Day Moving Average | 1.28 |
| 200-Day Moving Average | 1.31 |
| Relative Strength Index (RSI) | 35.21 |
| Average Volume (20 Days) | 730,180 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, KLSE:DPHARMA had revenue of MYR 916.83 million and earned 92.54 million in profits. Earnings per share was 0.10.
| Revenue | 916.83M |
| Gross Profit | 367.15M |
| Operating Income | 139.62M |
| Pretax Income | 121.58M |
| Net Income | 92.54M |
| EBITDA | 176.66M |
| EBIT | 139.62M |
| Earnings Per Share (EPS) | 0.10 |
Balance Sheet
The company has 270.65 million in cash and 484.69 million in debt, with a net cash position of -214.04 million or -0.22 per share.
| Cash & Cash Equivalents | 270.65M |
| Total Debt | 484.69M |
| Net Cash | -214.04M |
| Net Cash Per Share | -0.22 |
| Equity (Book Value) | 757.35M |
| Book Value Per Share | 0.79 |
| Working Capital | 510.30M |
Cash Flow
In the last 12 months, operating cash flow was 99.06 million and capital expenditures -25.19 million, giving a free cash flow of 73.87 million.
| Operating Cash Flow | 99.06M |
| Capital Expenditures | -25.19M |
| Depreciation & Amortization | 37.04M |
| Net Borrowing | -19.73M |
| Free Cash Flow | 73.87M |
| FCF Per Share | 0.08 |
Margins
Gross margin is 40.05%, with operating and profit margins of 15.23% and 10.09%.
| Gross Margin | 40.05% |
| Operating Margin | 15.23% |
| Pretax Margin | 13.26% |
| Profit Margin | 10.09% |
| EBITDA Margin | 19.27% |
| EBIT Margin | 15.23% |
| FCF Margin | 8.06% |
Dividends & Yields
This stock pays an annual dividend of 0.05, which amounts to a dividend yield of 3.76%.
| Dividend Per Share | 0.05 |
| Dividend Yield | 3.76% |
| Dividend Growth (YoY) | 51.67% |
| Years of Dividend Growth | 2 |
| Payout Ratio | 47.30% |
| Buyback Yield | -0.06% |
| Shareholder Yield | 3.70% |
| Earnings Yield | 7.95% |
| FCF Yield | 6.35% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Analyst Forecast
The average price target for KLSE:DPHARMA is 1.69, which is 37.40% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | 1.69 |
| Price Target Difference | 37.40% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 5 |
| Revenue Growth Forecast (3Y) | 4.26% |
| EPS Growth Forecast (3Y) | 8.78% |
Stock Splits
The last stock split was on September 6, 2021. It was a forward split with a ratio of 1.3333333333.
| Last Split Date | Sep 6, 2021 |
| Split Type | Forward |
| Split Ratio | 1.3333333333 |
Scores
KLSE:DPHARMA has an Altman Z-Score of 2.87 and a Piotroski F-Score of 6. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 2.87 |
| Piotroski F-Score | 6 |